Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 1,520,000 shares, a growth of 23.6% from the November 30th total of 1,230,000 shares. Currently, 4.6% of the company’s stock are sold short. Based on an average daily trading volume, of 744,600 shares, the days-to-cover ratio is presently 2.0 days.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ:HOWL traded down $0.02 during trading on Tuesday, reaching $1.46. 147,550 shares of the company’s stock traded hands, compared to its average volume of 379,643. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The company has a 50 day moving average of $2.04 and a 200-day moving average of $2.20. Werewolf Therapeutics has a 12 month low of $1.38 and a 12 month high of $8.19. The stock has a market capitalization of $65.05 million, a P/E ratio of -0.95 and a beta of 0.30.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new position in Werewolf Therapeutics during the third quarter worth about $29,000. Point72 DIFC Ltd acquired a new position in shares of Werewolf Therapeutics in the second quarter worth $34,000. XTX Topco Ltd purchased a new position in Werewolf Therapeutics in the third quarter valued at about $45,000. Rhumbline Advisers acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at about $79,000. Finally, American Century Companies Inc. grew its position in Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after acquiring an additional 12,656 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.